{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Marrakchi S, Guigue P, Renshaw BR., Puel A, Pei XY., Fraitag S, et al. Interleukin-36-recepto:', 'antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 2011;365:620-8.', 'Marrakchi S, Burden A, Tsai T, et al. Inhibition of the Interleukin-36 Pathway for the Treatment', 'of', 'Generalized Pustular Psoriasis [To the Editor]. N. Engl. J. Med. 2019; 380:10', 'Mahil S, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, et al. AP1S3 Mutations', 'Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36', 'Production. J of Invest Dermatol. 2016;136:2251-59.', 'Navarini A, Burden A, Capon F, Mrowietz U, Puig L, Koks S. European consensus statement on', 'phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799.', 'Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I, et al. Generalized', 'pustular psoriasis in Japan: Two distinct groups formed by differences in symptoms and genetic', 'background. Acta Derm Venereol (Stockh).1996;76:68-71.', 'Oji V, Luger T. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015;33', '(suppl. 93) S14-S19.', 'Onoufriadis A, Simpson M. A, Pink A. E, Di Meglio P, Smith C. H, Pullabhatla V, et al.', 'Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease', 'known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011;89:432-7.', 'Sugiura K, Takeichi T, Kono M, Ogawa Y, Shimoyama Y, Muro Y, et al. A novel', 'IL36RN/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult', 'onset generalized pustular psoriasis. Br. J. Dermatol. 2012;167:699-701.', '29 October 2019', '56']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '11.0 APPENDICES', '29 October 2019', '57']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 1', 'Abbreviations', 'Abbreviation', 'Definition', 'ADA', 'Anti-drug antibodies', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'ALT', 'Alanine aminotransferase', 'AST', 'Aspartate aminotransferase', 'ATC', 'Anatomical Therapeutic Chemical', 'AUC', 'Area under the concentration-time curve', 'BMI', 'Body mass index', 'BSA', 'Body surface area', 'CGI', 'Clinical Global Impression', 'CI', 'Confidence interval', 'Cmax', 'Maximum observed concentration', 'CRF', 'Case report form', 'CRP', 'C-reactive protein', 'CSR', 'Clinical Study report', 'CV', 'Coefficient of variation', 'DLQI', 'Dermatology Life Quality Index', 'DNA', 'Deoxyribonucleic acid', 'DRE', 'Disease-related events', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form', 'EOS', 'End of study', 'ET', 'Early termination', 'FAS', 'Full Analysis Set', 'FSH', 'Follicle stimulating hormone', 'GLP', 'Good Laboratory Practices.', 'GPP', 'Generalized pustular psoriasis', 'GPPPGA', \"Generalized Pustular Psoriasis Physician's Global Assessment\", 'IB', \"Investigator's Brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', '29 October 2019', '58']\n\n###\n\n", "completion": "END"}